Tanvex BioPharma released its 2025 financial results, reporting consolidated revenue of NT$401 million, a more than 10-fold increase year-on-year. While the company posted a net loss of NT$1.5 billion (EPS -$6.13) due to one-time integration costs, management views 2025 as the "Strategic Foundation Year."

• Operational Efficiency: Following the merger with Bora Pharmaceuticals' macromolecule CDMO business in January 2025, revenue has grown quarter-over-quarter. Revenue per employee surged by over 660%, signaling a significant lean-optimization of the workforce.
• Project Milestones: The company successfully launched its biosimilar TX-01 in partnership with Cipla, generating NT$190 million. Its CDMO business across Zhubei and San Diego added 35 new projects in 2025.
• Global Success: The Zhubei facility assisted the Australian firm Q-Sera in process development; the resulting product has already been launched in Japan by Terumo, marking Tanvex’s first international project to move from development to full commercialization. CEO Stephen Lam expects 2026 to be the year where the 2,000L capacity in San Diego begins to drive true economies of scale.

Resource: 泰福-KY去年每股虧6.13元 CDMO整合完成營收年增逾10倍